ImmunoCellular Therapeutics, Ltd Announces 55% Overall Survival at Three years from Phase I Study in Glioblastoma

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Three-year overall survival is 55% compared to 16% based on historical standard of care (SOC). The data show that 38% of newly diagnosed patients who received ICT-107 continue to show no tumor recurrence after three years, compared to the historic disease-free survival rate of 6% with SOC. Out of these patients, 19% remain disease-free after more than four years.